Putnam Associates Study Finds Insurers Want More Prescription Drug Use

Putnam Associates released today the results of an intensive study of U.S. health insurance plans' perceptions of branded prescription drug use in the U.S. The study revealed that plans believe greater pharmacoeconomic value can be unlocked by increasing patient use within certain drug categories.

Rising healthcare expenses have insurance companies desperate to cut costs, and many worry this will prompt increasing restrictions across the board on patient prescription drug coverage. However, Putnam discovered 8 classes of drugs, accounting for over $100 billion in sales, where insurers believe that increasing the number of patients on therapies and getting those patients with prescriptions to take their drugs would create value for both patients and plans in the long term.

Plans' interest in seeing increased appropriate use suggests there is opportunity for pharmaceutical manufacturers to align with them on certain drug categories. "The common ground between health plans and pharmaceutical manufacturers is around appropriate use, as these conversations can unlock value and address needs for both parties," says Richard Tinsley, Partner at Putnam Associates. He adds, "Our study shows there is clear agreement and opportunity for expanded appropriate use in many categories while in others there is less agreement. One of the key challenges for a managed markets team is how to address these issues at a portfolio level."

Putnam Associates researchers spoke to health care plan decision-makers who collectively insure 62% of the privately insured U.S. population, or roughly 124 million individuals. Insurers were asked to consider both underuse and over use of branded prescription drugs across 18 drug categories. Of the 18 categories, 8 were identified as being underused.

To download a copy of "U.S. Managed Markets: Opportunities and Risks in the Emerging Appropriate Use Paradigm" visit http://www.putassoc.com/company/pub_usmanaged.html

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...